ALTO-207 program advances; top-line data expected in 2027
ALTO-207 leads a three-trial PACE program in treatment-resistant depression, with top-line data expected in 2027. The platform highlights enhanced patient screening and precision biomarker strategies.
Story updates
02:36:59 PM UTC
SquawkNews
The conference highlighted a robust late-stage pipeline focused on precision psychiatry, with ALTO-207 leading a three-trial program in treatment-resistant depression and phase II-B data expected in H2 2027. ALTO-300 and ALTO-100 are advancing with biomarker-driven and novel mechanisms, while opera…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.